Supriya Lifescience

Supriya Lifescience Total Assets

The Total Assets of Supriya Lifescience (SUPRIYA.NS) as of Oct 22, 2026 is 13.57 B INR. In the previous year, Total Assets was 11.12 B INR — a change of 22.01% (higher).

Total Assets

13.57 BINR

YoY

22.01%

Last updated:

Total Assets of Supriya Lifescience is 2026 13.57 B INR. Total Assets of Supriya Lifescience was 2025 11.12 B INR. It decreases by 22.01% higher compared to the previous year.

The Supriya Lifescience Total Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Total Assets
Date
Total Assets
Jan 1, 2019
2.53 B INR
Jan 1, 2020
3.36 B INR
Jan 1, 2021
4.46 B INR
Jan 1, 2022
7.35 B INR
Jan 1, 2023
8.20 B INR
Jan 1, 2024
9.21 B INR
Jan 1, 2025
11.12 B INR
Jan 1, 2026
13.57 B INR
The Supriya Lifescience Total Assets history
YEARTotal AssetsYoY
13.57 BINR+22.01%
11.12 BINR+20.74%
9.21 BINR+12.31%
8.20 BINR+11.64%
7.35 BINR+64.81%
4.46 BINR+32.52%
3.36 BINR+32.95%
2.53 BINR+3.12%
2.45 BINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Supriya Lifescience Stock analysis

What does Supriya Lifescience do? Supriya Lifescience Ltd. generates revenue through the manufacturing and export of active pharmaceutical ingredients (APIs) focused on niche therapeutic segments. The company produces approximately 38 API products, including Chlorphenamine Maleate, Pheniramine Maleate, and Cetirizine DiHCL, which address antihistamine, analgesic, vitamin, anesthetics, and anti-asthma therapies. These products are exported to around 86 countries, targeting pharmaceutical manufacturers and healthcare providers seeking specialized chemical compounds for drug formulations. The firm's manufacturing facilities in Maharashtra support the production of bulk drugs and pharmaceutical chemicals, with a strong emphasis on research and development to maintain its niche market position. The company's product portfolio includes specialized compounds such as Bisoprolol Fumarate, Nicorandil, and Mecobalamin, which cater to specific medical needs in cardiovascular and neurological treatments. By concentrating on high-demand therapeutic areas like antihistamines and anti-asthma solutions, Supriya Lifescience Ltd. serves pharmaceutical companies globally that require reliable sources of API raw materials. Its export-driven model ensures steady demand from international clients across diverse healthcare markets. Supriya Lifescience Ltd. leverages its research and development capabilities to develop and refine its API offerings, ensuring compliance with global pharmaceutical standards. The firm's focus on niche products allows it to differentiate itself in a competitive market, attracting buyers who prioritize specialized chemical solutions over generic alternatives. With a manufacturing base in Maharashtra, the company efficiently scales production to meet the growing global demand for its targeted therapeutic APIs. Supriya Lifescience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Supriya Lifescience stock

Total Assets of Supriya Lifescience is 13.57 B INR in 2026.

Total Assets of Supriya Lifescience changed from 11.12 B INR to 13.57 B INR, representing a 22.01% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Assets Supriya Lifescience since 2006 – with annual values, charts, and detailed analysis.

Total assets represent everything a company owns, including cash, inventory, property, and intangible assets. It is a key measure of a company's size and resource base.

Total Assets's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Assets's Supriya Lifescience historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Supriya Lifescience

All Key Metrics — Supriya Lifescience